In this free webinar, gain an introduction to antiviral defenses in producer cells, their impact on adeno-associated virus (AAV) manufacturing and the current knowledge landscape. Attendees will learn the implications of antiviral defenses on viral vector quality metrics. The featured speakers will discuss a novel strategy to tackle the complex problem of antiviral defenses in production systems. Attendees will gain insights into the future of viral vector manufacturing as it pertains to the biotech industry.
TORONTO, Ontario, May 24, 2023 /PRNewswire-PRWeb/ -- Viral-based gene therapies comprise a key segment of the biotherapeutic landscape and are highly promising advancements for the treatment of complex and rare diseases. While adeno-associated virus (AAV) has emerged as the leading delivery vehicle for gene therapy, its growing demand has significantly strained the manufacturing supply. Viral medicine manufacturers have sought various innovative solutions to resolve this manufacturing bottleneck; however, there is mounting evidence that antiviral defenses are an important but often overlooked barrier to viral vector manufacturing. This intrinsic cellular immunity that is partially, if not wholly, present in manufacturing cell lines has surfaced as a key modulator for viral vector yield and quality.
This webinar will address the cascading impacts of antiviral defenses on viral vector manufacturing. The growing interest in unraveling viral vector quality metrics beyond yield increase via raw titers will be discussed, with an emphasis on the importance of functional viral yield.
Register for the webinar to learn about the impact of antiviral defenses on viral vector production systems, a solution to tackle viral defenses with a simple media additive and the future of viral vector manufacturing for the biotech industry.
Join experts from Virica Biotech, Dr. Jean-Simon Diallo, CEO; Dr. Jondavid de Jong, VP Scientific Operations; and Benjamin McLeod (Moderator), Technical Lead, for the live webinar on Tuesday, June 13, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Viral Vector Manufacturing — Are Antiviral Defenses the Missing Link to Scalability?
ABOUT VIRICA BIOTECH
Virica is the first company to develop and commercialize Viral Sensitizers (VSE™) as a solution to the challenge of Antiviral Defenses in the manufacturing of viral vectors. VSEs are patented small molecules, including known drugs and novel synthetic compounds, that transiently attenuate antiviral pathways in cells and, thus, can increase both virus production and the therapeutic efficacy of viral medicines.
Virica's VSE platform evolved from research conducted by Dr. Jean-Simon Diallo, Virica's Scientific Founder and CEO and a world-recognized leader in oncolytic viral therapies, at the Ottawa Hospital Research Institute (OHRI). Dr. Diallo and his team have developed unique high-throughput virology methods that have to date identified over 100+ VSEs.
Our services include formulation development with off-the-shelf or custom solutions as well as in-house evaluation or at-site evaluation support.
Learn more at viricabiotech.com or visit us on LinkedIn.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: [email protected]
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article